Merck & Company, Inc. Press Releases

MRK 
$56.05
*  
0.48
 negative 
0.86%
Get MRK Alerts
*Delayed - data as of Apr. 15, 2014 
Exchange: NYSE
Industry: Health Care
Community Rating:
View:    MRK Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

FDA Approves Merck’s GRASTEK® (Timothy Grass Pollen Allergen Extract) Sublingual Tablet as Immunotherapy to Treat Grass Pollen-Induced Allergic Rhinitis with or without Conjunctivitis in Children and Adults
4/14/2014 5:59:00 PM - Business Wire

Merck’s Investigational Chronic Hepatitis C Combination Therapy MK-5172/MK-8742 Demonstrates Antiviral Activity in Hard-to-Cure Patients with HCV Genotype 1 Infection
4/11/2014 1:00:00 AM - Business Wire

Merck Announces Results from Studies Evaluating Investigational Hepatitis C Treatments, MK-5172 and MK-8742, in Treatment-Naïve Patients with Genotype 1 Infection
4/10/2014 1:00:00 AM - Business Wire

Technical Pointers on Pharmaceuticals Equities -- Research on Merck, Bristol-Myers Squibb, Johnson & Johnson, and Eli Lilly
4/7/2014 12:34:00 PM - PR Newswire

Early Findings Exploring the Relationship of PD-L1 Expression and Clinical Outcomes with MK-3475, Merck’s Investigational Anti-PD-1 Immunotherapy, Presented at AACR Annual Meeting 2014
4/6/2014 10:30:00 AM - Business Wire

Merck, Ferring Pharmaceuticals and the World Health Organization Working Together to Prevent Excessive Bleeding in Women after Childbirth
4/4/2014 8:00:00 AM - Business Wire

Positive Opinions, Presentation Schedules of Investigational Data, Clinical Study Results, and Stock Price Movements - Analyst Notes on Johnson & Johnson, Merck, Pfizer, Amgen, and Allergan
3/28/2014 8:00:00 AM - PR Newswire

Merck Announces Appointment of Robert M. Davis as Chief Financial Officer; Succeeds Peter N. Kellogg, Who Has Served in the Role Since 2007
3/27/2014 7:20:00 AM - Business Wire

Merck Licenses NanoBio Technology
3/26/2014 10:06:00 AM - PR Newswire

Merck to Present New Data for Investigational Hepatitis C Treatments MK-5172 and MK-8742 at EASL Annual Meeting/The International Liver Congress™ 2014
3/24/2014 7:30:00 AM - Business Wire

Merck and Endocyte Announce European CHMP Positive Opinions for VYNFINIT® (vintafolide) and Companion Imaging Agents FOLCEPRI® (etarfolatide) and NEOCEPRI® (Intravenous (IV) folic acid) in Patients with Platinum-Resistant ...
3/21/2014 8:05:00 AM - Business Wire

Merck to Hold First-Quarter 2014 Sales and Earnings Conference Call on April 29
3/20/2014 5:00:00 PM - Business Wire

Health Care Stocks Review -- Research on Bristol-Myers Squibb, Johnson & Johnson, Merck & Co. and Eli Lilly
3/19/2014 8:00:00 AM - PR Newswire

Approvals, Financial Results, and Stock Movements - Analyst Notes on Merck, Novartis, Raptor, Akorn, and Pacira
3/19/2014 8:00:00 AM - PR Newswire

FDA Approves Merck’s NOXAFIL® (posaconazole) Injection (18 mg/mL) for Intravenous Use
3/14/2014 1:40:00 PM - Business Wire

Collaborations, Treatment Approvals, New Solutions, Clinical Trial Results, and New Drug Applications - Analyst Notes on Biogen Idec, Johnson & Johnson, Express Scripts, Merck, and Forest Laboratories
3/12/2014 8:00:00 AM - PR Newswire

Merck’s Investigational Hepatitis C Treatment Regimen MK-5172/MK-8742 Shows Robust Anti-HCV Activity in HIV/HCV Co-Infected Patients with HCV Genotype 1 Infection
3/5/2014 4:15:00 PM - Business Wire

Merck’s Investigational HIV Therapy, Doravirine (MK-1439), Demonstrates Antiviral Activity in Phase 2B Study of Treatment-Naïve Adults
3/5/2014 12:15:00 PM - Business Wire

New 96-Week ACTG Study Results Presented at CROI 2014; First Large Study Comparing ISENTRESS® (raltegravir) Regimen to Two Protease Inhibitor Regimens in Previously Untreated Adults with HIV-1
3/5/2014 12:15:00 PM - Business Wire

ALK's partner in North America, Merck, presents data on investigational house dust mite sublingual allergy immunotherapy tablet
3/4/2014 5:45:00 PM - GlobeNewswire

Merck Announces Results from Phase 2b Study of MK-8237, an Investigational House Dust Mite Sublingual Allergen Immunotherapy Tablet
3/4/2014 5:30:00 PM - Business Wire

CHMP Issues Positive Opinion for Tablet Formulation of Merck’s NOXAFIL® (posaconazole)
2/28/2014 8:30:00 AM - Business Wire

Merck Announces Second-Quarter 2014 Dividend
2/25/2014 12:31:00 PM - Business Wire

Merck to Participate in the Citi 2014 Healthcare Conference
2/20/2014 5:00:00 PM - Business Wire

MSD Animal Health Receives Marketing Authorization from European Commission for BRAVECTO™ (fluralaner)
2/17/2014 3:00:00 AM - Business Wire